AbbVie Loses Maviret Patent in India, Ensuring Affordable Hepatitis C Care

Indian Patent Office Denies AbbVie’s Secondary Patent for Maviret

AbbVie has faced a significant setback in India as the Indian Patent Office has refused its application for a secondary patent for its Hepatitis C drug, Maviret. This decision is a crucial victory for ensuring continued access to affordable treatment options for millions of patients in India suffering from Hepatitis C. The refusal means AbbVie will not be able to extend its patent monopoly on the drug, a common strategy employed by pharmaceutical companies to prolong market exclusivity beyond the initial patent term.

Patent Plea Abandoned Amidst Opposition

The Indian Patent Office rejected AbbVie’s secondary patent plea after the pharmaceutical giant failed to contest the oppositions filed against its application. Sources indicate that AbbVie ultimately chose to abandon its application, a move that directly led to the patent office’s refusal. This strategic decision by AbbVie to not actively defend its claim suggests a potential assessment of the strength of the oppositions or a calculated risk that did not pay off. The abandonment effectively concedes the ground, preventing any further attempts to secure extended protection for Maviret through this specific route in India.

Ensuring Affordable Hepatitis C Treatment Access

The denial of the secondary patent is poised to maintain a competitive landscape for Hepatitis C treatment in India. Maviret, a pan-genotypic treatment for Hepatitis C virus (HCV) infection, is a vital medication for patients. By preventing AbbVie from extending its patent monopoly, the Indian patent system is upholding its commitment to public health and ensuring that generic versions of the drug can continue to be available at more affordable prices. This is particularly important in a country like India, where access to essential medicines at lower costs is a critical public health concern, allowing a larger patient population to benefit from advanced treatments.

Implications for Pharmaceutical Patent Strategies

This ruling has broader implications for pharmaceutical companies operating in India and for the country’s intellectual property regime. It underscores the robustness of the Indian Patent Office’s examination process and its willingness to scrutinize secondary patent applications, especially when significant public health concerns are involved. The decision serves as a reminder that patent extensions are not guaranteed and are subject to rigorous review and the ability of applicants to successfully navigate opposition proceedings. For AbbVie, this outcome means their effective market exclusivity for Maviret in India will adhere to the original patent timelines, impacting their long-term revenue projections for the drug in the region.